Synthetic Biologics' late-breaking SYN-004 abstract was accepted for poster presentation and will be available for viewing at DDW in Hall C at the Walter E. Washington Convention Center, as part of the "DDW Late-Breaker Posters" session.
Title: SYN-004, a Clinical Stage Oral Beta-Lactamase Therapy, Protects the Intestinal Microflora from Antibiotic-Mediated Damage in Humanized Pigs
Authors: Sheila Connelly1, Giovanni Widmer2, Jean Mukherjee2; Kevin Huynh2, J. Andrew Bristol1, Steven Hubert1, Joseph Sliman1, Saul Tzipori2, Michael Kaleko1
1Synthetic Biologics, Inc., Rockville, MD; 2Tufts Cummings School of Veterinary Medicine, North Grafton, MA
Two posters will be presented under the Respiratory Infections category all four days at ECCMID 2015 in Copenhagen, Denmark on 50 ePoster stations, as follows:
Title: Antibody Cocktail Effectively Treats Pertussis in a Baboon Disease Model
Authors: J. A. Maynard1, A. Nguyen1, E. Wagner1, J. Laber1, L. Goodfield2, W. Smallridge2, E. T. Harvill2, R. F. Wolf3, J. C. Papin3, S. Connelly4, J. A. Bristol4, M. Kaleko4
1Universty of Texas at Austin, Austin, TX, 2Penn State Univ., University Park, PA, 3Univ. of Oklahoma Health Science Center, Oklahoma City, OK, 4Synthetic Biologics, Rockville, MD
Title: Spontaneous Identification of Bordetella bronchiseptica in a Baboon Colony: Potential Ramifications for Bordetella pertussis Modeling
Authors: M. Kaleko1, A. Nguyen2, E. Wagner2, R. F. Wolf3, J. C. Papin3, S.Connelly1, J. A. Bristol1, J. A. Maynard2
1Synthetic Biologics, Rockville, MD, 2Universty of Texas at Austin, Austin, TX, 3Univ. of Oklahoma Health Science Center, Oklahoma City, OK
Lewis Barrett, BS, MBA, Senior Vice President, Commercial Strategy and Joseph A. Sliman, MD, MPH, Senior Vice President, Clinical & Regulatory Affairs will discuss the novel point-of-care preventive approach of SYN-004, the Company's lead pathogen-specific product candidate for the prevention of C. difficile infection. To listen to the C. diff Spores and More radio episode podcast replay via the internet click here.
Episode hosted by the C. diff Foundation, www.cdifffoundation.org
Synthetic Biologics will hold an investor conference call on Monday, March 16th, at 8:30 a.m. EDT. Interested parties should call 1-888-347-5280 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-902-4280 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=101639. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=101639, for 30 days after the call.
Jeffrey Riley, Synthetic Biologics' CEO, is scheduled to present on Tuesday, March 10, 2015 at 1:00 p.m. (Pacific Time). A live webcast of Synthetic Biologics' presentation can be accessed by logging onto the web at http://wsw.com/webcast/roth29/syn. After the presentation, a replay will be archived and accessible for 30 days at the same website.
Jeffrey Riley, CEO, was invited to participate on the following panel at the BIO CEO & Investor Conference 2015:
“Trust Your Gut”—Therapeutic Opportunities from the Microbiome
The panel will review emerging data that the bacterial colonies of the digestive system influence far more non-digestive systems than previously believed, while creating natural antibiotics and other compounds that may be an underleveraged source for efficient drug discovery.
Panel Moderator: Mark Breidenbach, PhD, Equity Research Group, H.C. Wainwright & Co.
Synthetic Biologics WON the BIO CEO & Investor Conference's "Buzz of BIO" contest in the Most Distinguished Public Company category!
Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 9, 2015, at 1:30 p.m. (ET) at the Waldorf Astoria in New York.
A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the internet at http://www.veracast.com/webcasts/bio/ceoinvestor2015/42118168151.cfm. After the presentation, a replay will be archived and accessible for 90 days at the same website.
Jeffrey Riley, CEO, will present at the Biotech Showcase 2015 Conference at 2:00 p.m. (PT) on Tuesday, January 13, 2015 in the Mission II Room at the Parc 55 Wyndham San Francisco-Union Square Hotel.
A live webcast of Synthetic Biologics' presentation may be accessed by logging onto the internet at http://edge.media-server.com/m/p/pqjict2k. After the presentation, a replay will be archived and accessible for 90 days at the same website.
Thank you to everyone for participating in the Buzz of BIO Contest, recognizing the most innovative companies at the 2015 BIO CEO & Investor Conference! On Monday, December 8, 2015, we were informed that Synthetic Biologics WON this year’s contest in the Most Distinguished Public Company category. For more information, visit this Buss of BIO webpage: https://www.bio.org/ceobuzzofbio.
As the winner of this category, Synthetic Biologics will receive one (1) complimentary registration to the 2015 BIO CEO & Investor Conference, as well as a complimentary “public company” presentation spot.
Thank you for supporting Synthetic Biologics!
Synthetic Biologics, Inc. is pleased to be one of ten biotechs nominated in the category of “Most Distinguished Public Company” as part of the Buzz of BIO Contest, in association with the 17th Annual BIO CEO & Investor Conference, which will feature leading private and emerging public companies on February 9-10, 2015, at the Waldorf Astoria in New York, NY.
Please vote and spread the word about Synthetic Biologics’ participation!
It's easy. Just visit http://www.bio.org/ceobuzzofbiovote starting Monday, December 1st, and vote for Synthetic Biologics under the “Most Distinguished Public Company” category.
Tell your friends and colleagues. Share your support on your social media (or link to ours). It takes mere seconds to bookmark the link, and you can vote once a day through December 5th at 5:00pm ET.
Winners will be announced the week of December 8, 2014.
Synthetic Biologics will hold an investor conference call on Friday, November 14th, at 8:30 a.m. EST. Interested parties should call 1-888-347-5280 (U.S. toll free), 1-855-669-9657 (Canada toll free), or +1 412-902-4280 (International), fifteen minutes before the start of the call to register. Registered callers on the toll free line may ask to be placed in the queue for the Question & Answer Session. The call will also be webcast over the Internet at http://www.videonewswire.com/event.asp?id=100975. If you are unable to participate during the live conference call, the webcast will be available for replay at the same URL, http://www.videonewswire.com/event.asp?id=100975, for 30 days after the call.
Synthetic Biologics' CEO, Jeffery Riley, will provide an overview of the anticipated clinical and regulatory pathway for SYN-010 to reduce the impact of methane producing organisms on C-IBS, including plans to file an Investigational New Drug (IND) application and initiate a Phase II dose-discovery and proof-of-mechanism clinical study in the second half of 2014. Keynote speaker, Mark Pimentel, M.D., FRCP(C), Director, GI Motility Program and Laboratory, Cedars-Sinai Medical Center and Chairman, Synthetic Biologics' C-IBS Clinical Advisory Board, will discuss his groundbreaking work that led to the discovery of SYN-010, including the association between the overproduction of methane gas by microorganisms in the gut and conditions such as C-IBS, as well as further detail for SYN-010 itself.
Interested parties may log in to the live webcast and for replay after the event over the Internet at SYN IBS Investor Day Webcast.